Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis-Reference-Cited by-同舟云学术

Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis

Published:2023-10-31 Issue:1 Volume:26 Page:1407-1416
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

McEwan Phil¹,Hafner Marco¹,Jha Vivekenand²,Correa-Rotter Ricardo³,Chernin Gil⁴,De Nicola Luca⁵,Villanueva Russell⁶,Wheeler David C.⁷,Barone Salvatore⁸,Nolan Stephen⁹,Garcia Sanchez Juan Jose¹⁰^ORCID

Affiliation:

1. Health Economics and Outcomes Research Ltd, Cardiff, UK

2. George Institute for Global Health India, New Delhi, India

3. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Mexico

4. Kaplan Medical Centre, Rehovet, Israel

5. University L. Vanvitelli-Dept. Advanced Medical and Surgical Sciences, Naples, Italy

6. Department of Adult Nephrology, National Kidney and Transplant Institute, Quezon City, Philippines

7. Department of Renal Medicine, University College London, London, UK

8. Global Medical Affairs, AstraZeneca, Gaithersburg, Maryland, United States

9. Global Medical Affairs, AstraZeneca, Cambridge, UK

10. Health Economic and Payer Evidence, AstraZeneca, Cambridge, UK

Funder